Analytical Data
-
Gene name
PSG6
- Application
-
Alternative Names
Pregnancy-specific beta-1-glycoprotein 6; PSBG-6; PSBG-10; CGM3; PSG10; PSG12; PSGGB
-
Species
Human
-
Source
Baculovirus
-
Tag
C-His
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q00889-2
-
Expression Region
Q35-H424
-
Protein Length
Partial
-
Molecular Weight
58 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
PSG6, or Pregnancy-Specific Glycoprotein 6, is part of a larger family of glycoproteins that play significant roles during pregnancy. These proteins are synthesized in the placenta and are believed to contribute to various physiological processes such as immune modulation, trophoblast invasion, and fetal development. Research on PSG6 has gained attention due to its potential implications in pregnancy-related disorders and its role in regulating maternal-fetal interactions. In particular, PSG6 has been linked to the suppression of maternal immune responses to protect the developing fetus from rejection, which is crucial given the genetic disparity between the mother and the fetus. Moreover, abnormalities in PSG expression levels have been associated with complications such as preeclampsia, fetal growth restriction, and miscarriage. Investigating the structural and functional characteristics of PSG6, as well as its interactions with other biomolecules, could provide insights into its precise role in placental physiology and pathology. Therefore, ongoing studies aim to elucidate the mechanisms underlying PSG6's function and its potential as a biomarker for monitoring pregnancy health, with the ultimate goal of improving maternal and fetal outcomes in clinical settings.
